Synthesis of novel polybrominated benzimidazole derivatives-potential CK2 inhibitors with anticancer and proapoptotic activity
Edyta Łukowska-Chojnacka , Patrycja Wińska , Monika Wielechowska , Martyna Poprzeczko , Maria Bretner
AbstractThe efficient method for the synthesis of novel cell permeable inhibitors of protein kinase CK2 with anticancer and proapoptotic activity has been developed. A series of polybrominated benzimiadazole derivatives substituted by various cyanoalkyl groups have been synthesized. Cyanoethyl derivatives were obtained by Michael type addition of 4,5,6,7-tetrabromo-1H-benzimidazole (TBBi) and 4,5,6,7-tetrabromo-2-methyl-1H-benzimidazole to acrylonitrile, whilst cyanomethyl, cyanopropyl and cyanobutyl analogs by N-alkylation of 4,5,6,7-tetrabromo-1H-benzimidazole and 4,5,6,7-tetrabromo-2-methyl-1H-benzimidazole with appropriate cyanoalkyl halides. The inhibitory activity against protein kinase rhCK2α catalytic subunit and cytotoxicity against two human cancer cell lines: acute lymphocytic leukemia (CCRF-CEM) and breast (MCF-7) were evaluated for all newly synthesized compounds. Additionally, the proapoptotic activity toward leukemia cells and intracellular inhibition of CK2 for the most cytotoxic derivatives have been performed, demonstrating 4,5,6,7-tetrabromo-2-methyl-1H-benzimidazole as a new selective inhibitor of rhCK2 with twenty-fold better proapoptotic activity than parental compound (TBBi).
|Journal series||Bioorganic & Medicinal Chemistry, ISSN 0968-0896, (A 30 pkt)|
|Publication size in sheets||0.5|
|Keywords in English||4,5,6,7-tetrabromo-1H-benzimidazole derivatives; kinase CK2; inhibition; cytotoxicity; apoptosis|
|ASJC Classification||; ; ; ; ; ;|
|Score|| = 25.0, 10-09-2019, ArticleFromJournal|
= 30.0, 10-09-2019, ArticleFromJournal
|Publication indicators||= 14; = 17; : 2016 = 0.969; : 2016 = 2.93 (2) - 2016=2.88 (5)|
* presented citation count is obtained through Internet information analysis and it is close to the number calculated by the Publish or Perish system.